Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
200 participants
INTERVENTIONAL
2023-09-12
2025-12-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Optimal Timing of Vaccination in Pregnancy
NCT06466629
Pertussis (Tdap) Vaccination in Pregnancy
NCT01698346
Vaccination In Pregnancy Gene Signature: VIP Signature Study
NCT03284515
Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand
NCT02408926
Knowledge of Pregnant Women Concerning Pertussis, Vaccination Against Pertussis and Cocooning Strategy
NCT06114160
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Determine the impact of pregnancy on the quality of antibody response to pertussis immunization and identify immune predictors of vaccine responses in pregnant and non-pregnant women.
2. Identify immune predictors of the transfer of maternal antibodies to the newborn and the presence of antibody in breastmilk following pertussis immunization during pregnancy.
3. Determine the impact of maternal antibodies on the quality of antibody response to pertussis immunization in infants born to mothers immunized or not immunized during pregnancy and identify immune predictors of vaccine responses in the first months of life.
To reach these objectives, 40 non-pregnant and 80 pregnant women will be recruited into the study and vaccinated with a single dose of a pertussis containing vaccine (Triaxis). Blood samples will be collected from:
* non-pregnant women: before vaccination, and day 1/7/28 and month 5 post-vaccination.
* pregnant women: before vaccination, day 1/7/28 post-vaccination, at delivery, and week 6/12 post-delivery. At week 6/12 post-delivery, breast milk samples will be collected as well.
At delivery, a placenta fragment will be collected.
In addition, infants 2-3 months old born either from mothers who were not vaccinated against pertussis during pregnancy (n=40) or born from mothers who were vaccinated against pertussis during pregnancy (n=80) will be recruited in the study. Infants will be vaccinated with three doses of a pertussis containing vaccine (Vaxelis), each one month apart starting from 2-3 months of age. Blood samples will be collected from:
* infants from vaccinated mothers: cord blood, before 1st vaccine dose, day 1 post 1st vaccine dose, before 3rd vaccine dose, and day 28 post 3rd vaccine dose.
* infants from unvaccinated mothers: before 1st vaccine dose, day 1 post 1st vaccine dose, before 3rd vaccine dose, and day 28 post 3rd vaccine dose.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
* Infants born to Tdap vaccinated-mothers (enrolled or not in the study) or not vaccinated mothers will be recruited
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pregnant women
Pregnant women will receive one dose of Pertussis-containing vaccine during pregnancy.
Triaxis® (Pertussis-containing vaccine)
Triaxis® (Pertussis-containing vaccine) will be administered:
* in non-pregnant women presenting to the Travel and Vaccine clinic for pertussis immunization only or hospital member staff requiring Tetanus Toxoid (TT)-booster immunisation
* in Pregnant women between 16 and 29 weeks of gestation.
Non pregnant women
Non-Pregnant women will receive one dose of Pertussis-containing vaccine.
Triaxis® (Pertussis-containing vaccine)
Triaxis® (Pertussis-containing vaccine) will be administered:
* in non-pregnant women presenting to the Travel and Vaccine clinic for pertussis immunization only or hospital member staff requiring Tetanus Toxoid (TT)-booster immunisation
* in Pregnant women between 16 and 29 weeks of gestation.
Infants born to Tdap-vaccinated mothers
Infants whose mothers have been immunized during pregnancy with Tdap vaccine. Infants will receive three doses of Pertussis-containing vaccine (with 28 days interval starting at two months of age).
Vaxelis® (Pertussis-containing vaccine)
Vaxelis® (Hexavalent vaccine) will be proposed in infants at 8, 12 and 16 weeks of life.
Infants born to non Tdap-vaccinated mothers
Infants whose mothers have not been immunized during pregnancy with Tdap vaccine.
Infants will receive three doses of Pertussis-containing vaccine (with 28 days interval starting at two months of age).
Vaxelis® (Pertussis-containing vaccine)
Vaxelis® (Hexavalent vaccine) will be proposed in infants at 8, 12 and 16 weeks of life.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Triaxis® (Pertussis-containing vaccine)
Triaxis® (Pertussis-containing vaccine) will be administered:
* in non-pregnant women presenting to the Travel and Vaccine clinic for pertussis immunization only or hospital member staff requiring Tetanus Toxoid (TT)-booster immunisation
* in Pregnant women between 16 and 29 weeks of gestation.
Vaxelis® (Pertussis-containing vaccine)
Vaxelis® (Hexavalent vaccine) will be proposed in infants at 8, 12 and 16 weeks of life.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* For infants Born to mothers vaccinated or not with Tdap Vaccinated with hexavalent vaccine Age between 2 and 3 months
Exclusion Criteria
* Inability to understand the nature and extent of the study and the procedures required
* Grade III/IV anemia,
* Acute infection at the time of immunization
* Chronic infections such as Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) infection, acute toxoplasmosis
* Current or recent use of immunosuppressive drugs
* Active neoplasia
* Other vaccine(s) administered at the same time as Tdap vaccination (wash out of 4 weeks after others vaccinations and 28 days after Tdap vaccination )
* For pregnant women
* Risk of premature delivery or intrauterine growth retardation
* Twin or triplet pregnancies
* For non-pregnant women Last Tdap vaccination \< 12 months before
For infants:
* Infants born before 35 weeks of gestation
* Birthweight below 2.5 kg,
* Severe neonatal distress
* Serious congenital abnormalities or congenital infection.
2 Months
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Saint Pierre
OTHER
Université Libre de Bruxelles
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tessa Goetghebuer
Head of Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Saint-Pierre
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Marchant A, Sadarangani M, Garand M, Dauby N, Verhasselt V, Pereira L, Bjornson G, Jones CE, Halperin SA, Edwards KM, Heath P, Openshaw PJ, Scheifele DW, Kollmann TR. Maternal immunisation: collaborating with mother nature. Lancet Infect Dis. 2017 Jul;17(7):e197-e208. doi: 10.1016/S1473-3099(17)30229-3. Epub 2017 Apr 19.
Gunn BM, Alter G. Modulating Antibody Functionality in Infectious Disease and Vaccination. Trends Mol Med. 2016 Nov;22(11):969-982. doi: 10.1016/j.molmed.2016.09.002. Epub 2016 Oct 15.
Jennewein MF, Alter G. The Immunoregulatory Roles of Antibody Glycosylation. Trends Immunol. 2017 May;38(5):358-372. doi: 10.1016/j.it.2017.02.004. Epub 2017 Apr 3.
Jennewein MF, Abu-Raya B, Jiang Y, Alter G, Marchant A. Transfer of maternal immunity and programming of the newborn immune system. Semin Immunopathol. 2017 Nov;39(6):605-613. doi: 10.1007/s00281-017-0653-x. Epub 2017 Oct 2.
Jennewein MF, Goldfarb I, Dolatshahi S, Cosgrove C, Noelette FJ, Krykbaeva M, Das J, Sarkar A, Gorman MJ, Fischinger S, Boudreau CM, Brown J, Cooperrider JH, Aneja J, Suscovich TJ, Graham BS, Lauer GM, Goetghebuer T, Marchant A, Lauffenburger D, Kim AY, Riley LE, Alter G. Fc Glycan-Mediated Regulation of Placental Antibody Transfer. Cell. 2019 Jun 27;178(1):202-215.e14. doi: 10.1016/j.cell.2019.05.044. Epub 2019 Jun 13.
Jennewein MF, Kosikova M, Noelette FJ, Radvak P, Boudreau CM, Campbell JD, Chen WH, Xie H, Alter G, Pasetti MF. Functional and structural modifications of influenza antibodies during pregnancy. iScience. 2022 Mar 16;25(4):104088. doi: 10.1016/j.isci.2022.104088. eCollection 2022 Apr 15.
Tsang JS. Utilizing population variation, vaccination, and systems biology to study human immunology. Trends Immunol. 2015 Aug;36(8):479-93. doi: 10.1016/j.it.2015.06.005. Epub 2015 Jul 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B0762022220909
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.